Fennec Pharmaceuticals Inc. filings document formal disclosures for its commercial specialty pharmaceutical business, PEDMARK® product updates, and Nasdaq-listed common shares. Recent Form 8-K reports cover financial results, scientific presentations and investigator-sponsored studies involving sodium thiosulfate injection, and a license agreement resolving litigation tied to a proposed generic version of PEDMARK.
The company’s proxy materials cover director elections, board composition, executive compensation, equity awards, and shareholder voting matters. Other current reports disclose governance changes, registered common shares with no par value, and exhibits furnished with press releases concerning business, clinical, and product-related developments.
FENNEC PHARMACEUTICALS INC. ownership update: 1,981,501 common shares (CUSIP 31447P100) are reported as beneficially owned, representing 5.7% of the class. The disclosure is a joint filing by AIGH Capital Management LLC, AIGH Investment Partners LLC and Orin Hirschman and shows sole voting and dispositive power over these shares.
The filing lists the filers' principal business address and states the signature date as 04/28/2026. This is a routine Schedule 13G ownership disclosure under Rule 13d-1.
Fennec Pharmaceuticals Inc. is holding a virtual annual and special shareholder meeting on June 10, 2026 to vote on key governance and compensation items. Shareholders of record at 5:00 p.m. EDT on April 13, 2026, each holding one vote per common share, may participate online.
Shareholders will elect five directors, appoint Haskell & White LLP as auditors, and cast advisory votes on executive compensation and on how often that say‑on‑pay vote should occur, with the board recommending every year. As of April 13, 2026, there were 34,712,756 common shares outstanding.
Special business includes increasing the share reserve under Fennec’s 2020 Equity Incentive Plan to 10,000,000 common shares, which the circular states equals about 28.81% of shares outstanding, and approving a separate 2026 Equity Inducement Plan covering up to 600,000 shares, primarily for newly hired employees. The proxy also details executive and director pay, outstanding options, and severance and change‑of‑control provisions for senior management.
Fennec Pharmaceuticals Inc. reported that four scientific abstracts involving its ototoxicity drug PEDMARK (sodium thiosulfate injection) have been accepted for presentation or publication at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
Two studies will be presented as posters, including a Japanese pediatric trial on delayed sodium thiosulfate and a randomized Phase 1 trial in men with metastatic germ cell tumors. Two additional PEDMARK-focused studies will appear as abstract-only publications, covering real-world feasibility in young adults and audiometric outcomes in adults with head and neck cancer. The company highlights PEDMARK as the first FDA-approved therapy to reduce cisplatin-related hearing loss in eligible pediatric patients, noting its clinical evidence from two Phase 3 trials and international approvals under the PEDMARQSI brand.
Fennec Pharmaceuticals Inc. reported that the University of Arizona Cancer Center has initiated an investigator-sponsored study evaluating PEDMARK® (sodium thiosulfate injection) in adolescent, young adult, and adult patients with head and neck and testicular cancers receiving cisplatin.
The company explains that cisplatin-based chemotherapy is widely used but can cause permanent hearing loss in a significant share of patients, and PEDMARK is already approved to reduce ototoxicity risk in pediatric patients with localized, non-metastatic solid tumors. The new independent, institution-led study is intended to further build real-world evidence for PEDMARK in broader cancer populations beyond those in the pivotal pediatric trials.
Cioffi Christiana Marie reported acquisition or exercise transactions in this Form 4 filing.
FENNEC PHARMACEUTICALS INC. Chief Strategy Officer Christiana Marie Cioffi reported compensation-related equity awards. She received incentive stock options for 120,000 common shares at $5.77 per share, expiring on March 31, 2036, under the 2020 Equity Incentive Plan. Performance share units and previously awarded restricted shares also vested, increasing her directly held common shares to 23,865 as of March 28, 2026.
FENNEC PHARMACEUTICALS INC. reported that Chief Executive Officer Jeffrey S. Hackman received an incentive stock option grant to purchase 200,000 common shares at $5.77 per share, expiring on March 31, 2036, under the company’s 2020 Equity Incentive Plan.
On March 31, 2026, one-third of these options become exercisable, with additional portions vesting monthly so that all 200,000 options are vested by March 31, 2029. Hackman also acquired additional common shares through the settlement of performance share units that vested on March 31, 2026 and through the release of previously restricted shares awarded on March 28, 2025.
FENNEC PHARMACEUTICALS director Rosty Raykov exercised stock options and sold shares in a largely pre-planned, tax-related transaction. On April 1, 2026, he exercised 15,598 stock options at $2.45 per share, acquiring the same number of common shares under a Rule 10b5-1 trading plan adopted on September 19, 2025. On the same date, he sold 10,946 common shares at $6.31 per share to satisfy tax obligations related to the option exercise, also under that plan. A day earlier, on March 31, 2026, he received 5,208 common shares as a grant released from prior restricted awards. After these trades, he directly owned 113,856 common shares, indicating he retained most of the exercised shares.
Sayad Pierre Sargis reported acquisition or exercise transactions in this Form 4 filing.
FENNEC PHARMACEUTICALS INC. Chief Medical Officer Pierre Sargis Sayad reported equity compensation activity. On March 31, 2026, he received incentive stock options for 120,000 common shares at $5.77 per share, expiring March 31, 2036, under the 2020 Equity Incentive Plan.
One-third of these options vest on March 31, 2027, with additional vesting monthly until fully vested by March 31, 2029. The filing also shows settlement of performance share units and release of restricted shares, bringing direct holdings to 20,679 common shares. All transactions reflect awards and vesting rather than open‑market trading.
FENNEC PHARMACEUTICALS INC. Chief Commercial Officer Terry L Evans received an incentive stock option grant covering 120,000 common shares at an exercise price of $5.77 per share. The options were granted under the 2020 Equity Incentive Plan and vest over time, with one-third exercisable as of March 31, 2027 and the remainder vesting monthly so that all are vested by March 31, 2029.
On the same date, Evans also acquired common shares through the settlement of performance share units that vested on March 31, 2026 and through the release of previously restricted shares awarded on March 28, 2025. Following these equity awards and releases, Evans directly holds 20,679 common shares and 270,000 stock options, reflecting routine compensation-related transactions rather than open-market buying or selling.
Andrade Robert reported acquisition or exercise transactions in this Form 4 filing.
FENNEC PHARMACEUTICALS INC. reported insider equity awards for Chief Financial Officer Robert Andrade. On March 31, 2026, he received incentive stock options to purchase 120,000 common shares at $5.77 per share under the 2020 Equity Incentive Plan, vesting monthly from March 31, 2027 until March 31, 2029.
On the same date, 14,724 common shares were issued from settlement of PSUs that vested, and 2,213 common shares were released from restriction from prior awards. On March 28, 2026, 12,270 additional common shares were released from restriction from a 2025 award. Following these transactions, he directly holds 273,593 common shares and 921,045 stock options.